Corcept Therapeutics CORT Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's operating lease liabilities?
- Corcept Therapeutics (CORT) reported operating lease liabilities of $8.01M in Q1 2026.
- How has Corcept Therapeutics's operating lease liabilities changed year-over-year?
- Corcept Therapeutics's operating lease liabilities increased by 36.9% year-over-year, from $5.85M to $8.01M.
- What is the long-term trend for Corcept Therapeutics's operating lease liabilities?
- Over 4 years (2020 to 2025), Corcept Therapeutics's operating lease liabilities has grown at a 77.9% compound annual growth rate (CAGR), from $501K to $5.02M.
- What does operating lease liabilities mean?
- The portion of lease payments due after more than one year.
- How do you interpret operating lease liabilities?
- An increase indicates long-term expansion or renewal of lease agreements, while a decrease suggests a reduction in long-term lease commitments.
- How does operating lease liabilities compare across companies?
- Standardized across industries; peers with owned versus leased facilities will show significant variance in this metric.